Drugs News and Research

RSS

Drug used to treat lung cancer could help improve survival rates for bladder cancer patients

Scientists from the University of Sheffield have discovered a drug already used to treat lung cancer could help to improve survival rates for bladder cancer patients.

11 Apr 2022

Study identifies several therapeutically effective drugs for bladder cancer

Hundreds of chemical compounds were screened on cell cultures representing different stages and subtypes of bladder cancer and several promising agents with inhibitory (growth-inhibiting) effects were identified.

11 Apr 2022

Drugs targeting DNA damage response pathway show therapeutic potential against advanced solid tumors

Results from early-stage clinical trials show two drugs that target the DNA damage response (DDR) pathway in cancers - ATR inhibitor elimusertib and PARP inhibitor AZD5305 - are safe and clinically beneficial in treating patients with advanced solid tumors.

11 Apr 2022

Discovery of key regulator of body weight could lead to new treatments for metabolic disorders

Yale scientists uncover key regulator of body weight. Yale scientists have discovered that a protein known as augmentor-alpha regulates body weight in mice, an insight that could lead to new treatments for metabolic disorders.

11 Apr 2022

Alternative anti-HIV strategy generates promising results in a phase I clinical trial

vaccines against the virus, but unfortunately, HIV has numerous defense mechanisms that prevent a person's immune system from mounting an effective response following HIV vaccination.

11 Apr 2022

Novel strategy can shrink tumors and prolong survival in mice

A research team based at the University of Ottawa and The Ottawa Hospital has developed a virus that infects and kills cancer cells without harming normal cells, while also sending out signals to prepare nearby uninfected cancer cells for viral attack.

11 Apr 2022

New study reveals oral opaganib's potent in vitro activity against Omicron

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced study results in which opaganib (ABC294640), a leading oral drug candidate for hospitalized patients with moderate to severe COVID-19, was observed to have potent in vitro efficacy against the Omicron SARS-CoV-2 variant, while maintaining host cell viability.

11 Apr 2022

Tobacco use increased in smokers trying to quit during COVID-19, study finds

While smoking rates have declined dramatically in the United States, there are still 35 million smokers. There are few data about whether, and if so, how current cigarette smoking habits among those trying to quit are affected by the COVID-19 pandemic.

11 Apr 2022

New research provides a scientific framework to allow the use of psilocybin for therapeutic reasons

A new paper by an Oregon State University-led research team provides a scientific framework to help shape the rollout of a program in Oregon that will legally permit the use of psilocybin for therapeutic reasons.

11 Apr 2022

Vaccines safely protect IBD patients from COVID-19

COVID-19 vaccines taken by people with inflammatory bowel disease (IBD), which affects millions worldwide, safely and effectively protects them from the SARS-Cov-2 virus, a Rutgers study finds.

11 Apr 2022

Study identifies a novel class of angiotensin receptor blockers that interfere with SARS-CoV-2 spike – ACE2 interaction

Scientists have discovered a new generation of angiotensin receptor blockers that may be used to treat coronavirus disease 2019.

11 Apr 2022

Bilingualism can slow down the course of age-related changes in the brain

Medical advances are causing a gradual increase in average life expectancy. However, this comes at a price, as the number of cases of dementia and other neurodegenerative diseases grows with age. Researchers from HSE University (Russia) and Northumbria University (UK) have found that bilingualism can slow down and mitigate the course of age-related changes in the human brain.

11 Apr 2022

Adding immunotherapy to chemotherapy before surgery improves outcomes for NSCLC patients

Adding the immunotherapy drug nivolumab to chemotherapy before surgery (neoadjuvant) for patients with operable non-small cell lung cancer (NSCLC) — the leading cause of cancer deaths worldwide — reduced the risk of recurrence of the cancer or death by more than one-third, according to results from the phase III CheckMate-816 trial.

11 Apr 2022

Safety profile of colchicine in COVID-19 patients

Researchers evaluated the use of colchicine in COVID-19 patients.

11 Apr 2022

What does the Future of Microfluidics within Research Look Like?

We speak to France Hamber, CEO of Fluigent, about their microfluidics solutions and how they are allowing scientists to focus more on the science than the setup.

From Fluigent 11 Apr 2022

Let’s Talk about Parkinson’s

In recognition of World Parkinson's Day, we speak to Dr. Arthur Roach, Director of Research at Parkinson’s UK, about the current Parkinson's landscape.

11 Apr 2022

Study: Less than half of clinical trials report race/ethnicity data

Clinical trials represent one the largest investments of collective resources in science. These studies, which recruit participants and rigorously evaluate new interventions and therapeutics, aim to advance scientific knowledge and improve patient treatment.

11 Apr 2022

Challenges, unmet needs and future opportunities in COVID-19 therapeutics

In a recent article published in the journal Proceedings of the National Academy of Sciences (PNAS), researchers reviewed the present-day therapeutic landscape of coronavirus disease 2019 (COVID-19) and addressed future opportunities to overcome challenges that hinder drug development and improve the global preparedness for future pandemics.

10 Apr 2022